Official Title
The Effectiveness of Testofen on Energy, Fatigue, Mental Acuity, and Other Quality of Life Symptoms Post COVID-19 Infection
Brief Summary

This is a double blind, randomised, placebo-controlled trial to evaluate orally-dosedTestofen (a specialised extract of Trigonella foenum-graecum (Fenugreek) seed) comparedto placebo on post COVID-19 symptoms in otherwise healthy participants 18 years and over.

Detailed Description

Not Provided

Recruiting
Long Covid19

Drug: Testofen

Twice daily dose of 1 capsule (300mg per capsule Testofen)

Drug: Microcrystalline cellulose

Twice daily dose of 1 capsule

Eligibility Criteria

Inclusion Criteria:

- Adults 18 years and over

- Able to provide informed consent

- Diagnosed with COVID-19 infection (RAT or PCR test) >4 weeks, but < 12 months and
experiencing post COVID symptoms (1)

- Agree not to participate in another clinical trial while enrolled in this trial

1. Common post COVID symptoms may include fatigue, cough, chest pain, hair loss,
weakness, joint pain, cardiac issues, neurocognitive impairment including
memory loss, and decreased quality of life

Exclusion Criteria:

- Symptoms resulting from vaccination (2)

- Unstable or serious illness (e.g., serious mood disorders, neurological disorders
such as MS, kidney disease, liver disease, heart conditions, diabetes, thyroid gland
dysfunction) (3)

- Current malignancy (excluding BCC) or chemotherapy and radiotherapy treatment for
malignancy within the previous 2 years

- Receiving/prescribed coumandin (Warfarin), heparin, dalteaparin, enoxaparin or other
anticoagulation therapy

- Receiving pharmaceutical treatment for anxiety, libido, low energy

- Active smokers, nicotine use, alcohol, or drug (prescription or illegal substances)
abuse

- Chronic past and/or current alcohol use (>14 alcoholic drinks per week)

- Allergic to any of the ingredients in the active or placebo formula

- Known pregnant or lactating women

- Any condition which in the opinion of the investigator makes the participant
unsuitable for inclusion

- Participants who have participated in any other related clinical study during the
past 1 month

- History of infection in the month prior to the study

(2) Symptoms must be as a direct result of having contracted COVID. If symptoms only
appeared within 2 weeks of a vaccination it will be considered a vaccine injury and
not classed as a result of COVID.

(3) An unstable illness is any illness that is currently not being treated with a
stable dose of medication or is fluctuating in severity. A serious illness is a
condition that carries a risk of mortality, negatively impacts quality of life and
daily function and/or is burdensome in symptoms and/or treatments.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Australia
Locations

RDC Clinical Pty Ltd
Brisbane, Queensland, Australia

Investigator: Amanda Rao, PhD
Contact: +61 414 488 559
amanda@rdcglobal.com.au

Contacts

Amanda Rao, PhD
+61 414 488 559
amanda@rdcglobal.com.au

David Briskey, PhD
+61 421 784 077
david@rdcglobal.com.au

Amanda Rao, PhD, Principal Investigator
RDC Clinical Pty Ltd

RDC Clinical Pty Ltd
NCT Number
MeSH Terms
COVID-19
Post-Acute COVID-19 Syndrome